NR3C2 and COVID-19: MR-proADM, copeptin and MR-proANP significantly correlate with the main adverse outcomes in severe COVID-19 patients admitted to the ICU during the first waves, likely deserving to be evaluated in the future together with the SOFA, SAPS II and MuLBSTA prognostic scores.